Innovation Task Force (ITF) briefing meeting request form
Submitted by Anonymous (not verified) on 18 December 2024 - 8:56
Innovation Task Force (ITF) briefing meeting request form
UPD refresher webinar for marketing authorisation holders on volume of sales submission, Online, from 5 December 2024, 10:00 (CET) to 5 December 2024, 11:00 (CET)
Submitted by Anonymous (not verified) on 18 December 2024 - 8:45
UPD refresher webinar for marketing authorisation holders on volume of sales submission, Online, from 5 December 2024, 10:00 (CET) to 5 December 2024, 11:00 (CET)
Minutes of the CHMP meeting 22-25 July 2024
Submitted by Anonymous (not verified) on 18 December 2024 - 8:25
Minutes of the CHMP meeting 22-25 July 2024
ICH Q4B Evaluation and recommendation of pharmacopoeial texts for use in the ICH regions - Scientific guideline
Submitted by Anonymous (not verified) on 18 December 2024 - 8:17
ICH Q4B Evaluation and recommendation of pharmacopoeial texts for use in the ICH regions - Scientific guideline
ICH Q4B(R1) Guideline on evaluation and recommendation of pharmacopoeial texts for use in the ICH regions - Step 5
Submitted by Anonymous (not verified) on 18 December 2024 - 8:16
ICH Q4B(R1) Guideline on evaluation and recommendation of pharmacopoeial texts for use in the ICH regions - Step 5
Frequently asked questions about parallel distribution
Submitted by Anonymous (not verified) on 18 December 2024 - 8:08
Frequently asked questions about parallel distribution
Human medicines European public assessment report (EPAR): Vizimpro, dacomitinib, Date of authorisation: 02/04/2019, Revision: 4, Status: Authorised
Submitted by Anonymous (not verified) on 17 December 2024 - 17:09
Human medicines European public assessment report (EPAR): Vizimpro, dacomitinib, Date of authorisation: 02/04/2019, Revision: 4, Status: Authorised
HMA / EMA Task Force on the Availability of Authorised Medicines for Human and Veterinary Use (2016-2024)
Submitted by Anonymous (not verified) on 17 December 2024 - 16:55
HMA / EMA Task Force on the Availability of Authorised Medicines for Human and Veterinary Use (2016-2024)
Data access to medicinal products for human use - Chapter 5 Annex A: Product data elements accessible by stakeholder group
Submitted by Anonymous (not verified) on 17 December 2024 - 16:50
Data access to medicinal products for human use - Chapter 5 Annex A: Product data elements accessible by stakeholder group
Good practice guidance for communication to the public on medicines’ availability issues
Submitted by Anonymous (not verified) on 17 December 2024 - 16:49
Good practice guidance for communication to the public on medicines’ availability issues